Eris Lifesciences - JV With MJ Biopharm To Widen Offerings In Diabetics Market: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Eris Lifesciences Ltd. announced its entry into India’s insulin and Glucagon-like peptide-1 agonists market through joint venture with MJ Biopharm Ltd.
The 70:30 joint venture (with Eris Lifesciences holding a 70% stake) will primarily engage in marketing and distribution of human and analogue insulin and GLP-1 agonists, along with potentially other biopharma products in India.
MJ Biopharm will be responsible for development, manufacturing and supply of these products to the joint venture.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.